Acquired PIK3CA amplification causes resistance to selective phosphoinositide 3-kinase inhibitors in breast cancer

Agents targeting the PI3K/mTOR signaling axis have shown promise in early-phase clinical trials and are currently being studied in later stages of clinical development in multiple indications. Experience with other targeted agents suggests that clinical responses may be short-lived because of acquir...

Descripción completa

Detalles Bibliográficos
Autores principales: Huw, L-Y, O'Brien, C, Pandita, A, Mohan, S, Spoerke, J M, Lu, S, Wang, Y, Hampton, G M, Wilson, T R, Lackner, M R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2013
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3940863/
https://www.ncbi.nlm.nih.gov/pubmed/24366379
http://dx.doi.org/10.1038/oncsis.2013.46

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3940863/
https://www.ncbi.nlm.nih.gov/pubmed/24366379
http://dx.doi.org/10.1038/oncsis.2013.46

Ejemplares similares